Tag: Hormones: Misc.
NAMS Updates Position Statement on Menopausal Hormone Therapy
Using best available evidence, treatment should be individualized to maximize benefits and minimize risks
Hormone Therapy-Related Hot Flashes Tied to Worse Breast Cancer Outcomes
Findings for chemotherapy-free patients with breast cancer
ADT + Pelvic Lymph Node Radiation Improves Prostate Cancer Outcomes
Five-year freedom from progression rate higher for those receiving short-term ADT and PLNRT in addition to salvage PBRT
Sex Hormone Deficiency May Up Risk for Rotator Cuff Repair
Odds of rotator cuff repair increased for women with estrogen deficiency and for men with testosterone deficiency
Adding ADT to Radiotherapy Ups Mets-Free Survival in Prostate Cancer
In meta-analysis, adjuvant ADT prolongation also linked to improvement in metastasis-free survival, but not neoadjuvant ADT extension
Mental Health Improves With Access to Gender-Affirming Hormones
Access to GAH during adolescence, adulthood linked to lower odds of past-year suicidal ideation versus desiring but not accessing GAH
Rates of Obesity, Weight Gain Up for Transmasculine Individuals
Prevalence of obesity and weight gain higher after hormone therapy for transmasculine versus transfeminine individuals
Five-Year Extended Hormone Therapy No Better in Breast Cancer
Findings compared with two years of extended adjuvant anastrozole in postmenopausal women with hormone-receptor-positive breast cancer
Erythropoietin May Up Risk for Hip Fracture in Hemodialysis Patients
Risk for hip fracture increased with EPO doses of 50 to 149, 150 to 299, and ≥300 versus <50 units/kg/week
Effect of COVID-19 on Breast Cancer Treatment Examined
More patients with estrogen receptor-positive, HER2-negative breast cancer treated with neoadjuvant endocrine therapy due to COVID-19
